Analysis of Analgesic Trials
Analgesic clinical trials are usually complex. Because of the complexity of these trials knowledge of pharmacokinetic/pharmacodynamic relationships of analgesics is limited. The consequence of this is that some recommended analgesic doses may not be optimal. The design of an analgesic clinical trial is usually of the following pattern; patients receive a single dose of an analgesic or a placebo after a pain-initiating event such as surgery, and pain intensity or pain relief is measured to assess drug efficacy at specific times after drug administration. On ethical grounds, the patients can demand a rescue medication of a known effective analgesic at any time if their pain relief is inadequate. Pain relief and remedication time—two clinical efficacy endpoints—are compared between placebo and the administered active doses of the analgesic tested.
KeywordsPlacebo Covariance Convolution Brom Ketorolac
Unable to display preview. Download preview PDF.
- Beal, S.L. and Sheiner, L.B. (1982). Estimating population pharmacokinetics. CRC Critical Review in Biomedical Engineering 8, 195–222.Google Scholar
- Beal, S.L. and Sheiner, L.B. (1992). NONMEM Users Guides, Parts I-VII. University of California, San Francisco, CA.Google Scholar
- Laska, E.M. Siegel, C., and Sunshine, A. (1991). Onset and duration: Meas- urement and analysis. Clinical Pharmacology and Therapeutics 49, 1–5.Google Scholar
- Mandema, J.W. (1997). Population pharmacokinetics/pharmacodynamics of analgesics: theory and applications. In: Aarons, L., Balant, L.P., Danhof, M., et al., eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Commission of the European Communities. European Cooperation in the Field of Scientific and Technical Research, Brussels, pp. 74–82.Google Scholar
- Mandema, J.W. and Stanski, D.R. (1996). Population pharmacodynamic model for ketorolac analgesia. Clinical Pharmacology and Therapeutics 60, 619635.Google Scholar
- Mandema, J.W., Verotta, D., and Sheiner, L.B. (1992). Building population pharmacodynamic models. I. Models for covariates. Journal of Pharmacokinetics and Biopharmaceuticals 20, 58–528.Google Scholar
- Max, M.B., Portenoy, R.K., and Laska, E.M., eds. (1991). Advances in pain research and therapy. Volume 18: The Design of Analgesic Clinical Trials. Raven Press, New York.Google Scholar
- Sheiner, L.B. (1994). A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clinical Pharmacology and Therapeutics 56, 3098–322.Google Scholar
- Sheiner, L.B., Stanski, D.R., Vozeh, D.R., and Miller, R.D. (1979). Simultaneous modeling of pharmacokinetics modeling of pharmacokinetic and pharmacodynamics: Application to D-tubocurarine. Clinical Pharmacology and Therapeutics 25, 358–371.Google Scholar
- Velagapudi, R., Harter, J.G., Brueckner, R., and Peck, C.C. (1991). Pharmacokinetic/pharmacodynamic models in analgesic study design. In: Max, M.B., Portenoy, R.K., Laska, E.M., eds. Advances in Pain Research and Therapy, Vol. 18. Raven Press, New York, pp. 559–562.Google Scholar
- Wajdula, J.S., Vavra, I., Sullivan, D., Ermer, J., and Osman, M. (1994). Bromfenac. In: Lewis, A.J., Furst, D.E., eds. Nonsteroidal Anti-Inflammatory Drugs: Mechanisms and Clinical Uses. Second edition. Marcel Dekker, New York, pp. 267–284.Google Scholar